Cargando…
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
BACKGROUND: In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp1...
Autores principales: | Revicki, Dennis A, van den Eertwegh, Alfons JM, Lorigan, Paul, Lebbe, Celeste, Linette, Gerald, Ottensmeier, Christian H, Safikhani, Shima, Messina, Marianne, Hoos, Axel, Wagner, Samuel, Kotapati, Srividya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426458/ https://www.ncbi.nlm.nih.gov/pubmed/22694829 http://dx.doi.org/10.1186/1477-7525-10-66 |
Ejemplares similares
-
Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019) -
Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019) -
Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013) -
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014) -
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)